EPT (N-Ethyl-N-propyltryptamine)
EPT is a lesser-known psychedelic tryptamine, the N-ethyl-N-propyl homolog in the DMT family. It has appeared as a research chemical with only fragmentary self-reports and no formal human or clinical data.
01 Overview
EPT (ethylpropyltryptamine) is one of many asymmetrically N,N-disubstituted tryptamines that have surfaced on the grey market. Its longer alkyl substituents place it near DPT and DET in the structural series.
There is no published pharmacology, toxicology or pharmacokinetics for EPT in humans. The values here are conservative estimates derived from scattered anecdote and structural analogy, and should be treated as highly uncertain.
02 Mechanism
Assumed serotonin 5-HT2A agonism common to classical tryptamine psychedelics; no direct binding data published.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light (reported) | 10–25 mg | Insufflated | Anecdotal. |
| Common (reported) | 25–50 mg | Oral | Anecdotal; may need an MAOI for reliable oral activity. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Psychedelic perceptual changesVisual and cognitive alteration typical of tryptamines, per limited self-reports. | moderate | Anecdotal | |
| IntrospectionSome users report reflective or emotionally open states. | variable | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| NauseaGut discomfort common with oral tryptamines. | Mild | Common | Anecdotal | |
| AnxietyFear and unease at higher doses. | Moderate | Common | Anecdotal |